Analytical Data
-
Gene name
ULBP2/NKG2DL2
-
简介
NKG2DL2 Protein activates KLRK1/NKG2D receptor, promoting natural killer cell cytotoxicity. Importantly, it does not bind beta2-microglobulin, confirmed by research findings. ULBP2/NKG2DL2 Protein, Human (HEK293, hFc) is the recombinant human-derived ULBP2/NKG2DL2 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
Alternative Names
ALCAN-alpha; N2DL2; NKG2DL2; RAET1H; RAET1L; ULBP2; ULBP-2/5/6; NKG2D ligand 2
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BZM5
-
Expression Region
G26-S216
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
55-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ULBP2 (Ulbp2) belongs to the NKG2D ligand family, which plays a crucial role in the regulation of immune responses, particularly in the recognition and elimination of tumor cells by natural killer (NK) cells and cytotoxic T lymphocytes. This protein binds to the NKG2D receptor, expressed on the surface of these immune cells, thereby triggering cytotoxic activity. Recent studies have highlighted the potential of ULBP2/NKG2DL2 as a therapeutic target in cancer immunotherapy, as its expression is often upregulated in various malignancies, contributing to immune evasion. Researchers have been focusing on the recombinant expression of ULBP2/NKG2DL2 proteins to better understand their structure-function relationships and the mechanisms underlying their interactions with immune cells. This research aims to develop novel immunotherapeutic strategies that could enhance the immune system's capacity to recognize and destroy cancer cells. By creating recombinant forms of ULBP2/NKG2DL2, scientists can investigate their role in modulating immune responses, assess their potential as biomarkers for cancer diagnosis and prognosis, and explore their use in engineered cell therapies. Overall, this research is relevant for advancing our understanding of immune regulation in cancer and developing innovative therapies that can improve patient outcomes.
